Скачать или смотреть Zanubrutinib Combined with Venetoclax for CLL Patients with Deletion 17p - Dr. Constantine Tam

Deletion of the short arm of chromosome 17 (del(17p)) in chronic lymphocytic leukemia (CLL) is associated with resistance to chemoimmunotherapies and worse outcomes for patients. However, targeted therapies provide new options for patients with del(17p). One new targeted therapy is zanubrutinib, a next-generation BTK inhibitor currently being tested in clinical trials for CLL.

Dr. Constantine Tam, a hematologist at the Peter McCallum Cancer Center in Melbourne, Australia, speaks about the SEQUOIA trial, a phase 3 trial testing the efficacy of zanubrutinib as a first-line treatment in patients with CLL / SLL. This study also looks at combining zanubrutinib and venetoclax (a BCL-2 inhibitor) for CLL treatment. Dr. Tam discusses results presented at the American Society of Hematology (ASH) annual meeting in 2021.

Read the full article on CLL Society's website at: https://cllsociety.org/2022/04/ash-20...
__________________________________________________________________________________________
CLL Society Website: https://cllsociety.org/
Facebook:   / cllsociety  
Twitter:   / cllsociety  
LinkedIn:   / cll-society